Pharmaceuticals, Biotechnology and Life Sciences
Inventiva, a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, has appointed Dr Nanna Lüneborg as its Board member, succeeding Mr Philippe Goupit.
A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday.
Bone Therapeutics has appointed Steve Swinson and Damian Marron to its Board of Directors as Non-Executive Directors.
The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity.
Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising $45 million.
The U.S. Food and Drug Administration (FDA) has approved Roche’s Actemra/RoActemra (tocilizumab) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition.
Therapix Biosciences, a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-based drugs, has announced that the company’s Chief Executive Officer Dr. Elran Haber will step down from his position to pursue other professional opportunities.
Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.
Horizon Pharma has reached an agreement to sell a European subsidiary that owns the marketing rights to Procysbi (cysteamine bitartrate) delayed-release capsules and Quinsair (levofloxacin inhalation solution) in Europe, the Middle East and Africa (EMEA) regions to Chiesi Farmaceutici S.p.A. (Chiesi) for an upfront payment of $70 million, with additional potential milestone payments based on sales targets.
Selexis SA and OSE Immunotherapeutics have signed a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform.